Publication of Annual Report 2021 & Notice of AGM
("Renalytix" or the "Company")
Publication of Annual Report 2021
and Notice of 2021 Annual General Meeting
https://investors.renalytix.com/news-and-events/documents-and-presentations
The 2021 Annual Report and the Notice of AGM will be posted to shareholders who have not consented to receive electronic communications.
The AGM will be held in-person on
Any Shareholder intending to attend will need to register first by contacting Walbrook PR via email at renalytix@walbrookpr.com or by telephone at +44 (0)20 7933 8790. If you are planning to attend in-person, please provide details for track and trace to Walbrook PR.
The Directors consider that the proposed resolutions contained in the Notice of Annual General Meeting are in the best interests of the Company and shareholders as a whole and unanimously recommend that you vote in favour of them, as they intend to do in respect of their own shareholdings.
Proxy voting
You will not receive a hard copy form of proxy for the Annual General Meeting in the post. Instead, you will be able to vote electronically using the link www.signalshares.com. You will need to log into your Signal Shares account, or register if you have not previously done so. To register you will need your Investor Code, this is detailed on your share certificate or available from our Registrar, Link Group.
You may request a hard copy form of proxy directly from Link Group at shareholderenquiries@linkgroup.co.uk or on +44 (0)371 664 0300. Calls are charged at the standard geographic rate and will vary by provider. Calls outside the
For further information, please contact:
|
|||
|
Via Walbrook PR |
||
|
|
||
Stifel (Nominated Adviser, Joint Broker) |
Tel: 020 7710 7600 |
||
|
|
||
|
|
||
|
Tel: 020 7597 4000 |
||
|
|
||
|
|
||
|
Tel: 020 7933 8780 or renalytix@walbrookpr.com |
||
|
Mob: 07980 541 893 / 07584 391 303 |
||
|
|
||
|
Tel: 415-389-6400 or investors@renalytix.com |
||
|
|
||
About Kidney Disease
Kidney disease is now recognized as a public health epidemic affecting over 850 million people globally. The
About KidneyIntelX
KidneyIntelX, is a first-of-kind solution that enables early-stage diabetic kidney diseases (DKD) progression risk assessment by combining diverse data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record, or EHR, systems, and employs a proprietary algorithm to generate a unique patient risk score. This patient risk score enables prediction of progressive kidney function decline in CKD, allowing physicians and healthcare systems to optimize the allocation of treatments and clinical resources to patients at highest risk.
About Renalytix
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the